Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration
about
sameAs
Impacts of tissue-type plasminogen activator (tPA) on neuronal survivalTissue-type plasminogen activator is a neuroprotectant in the central nervous systemReperfusion therapies of acute ischemic stroke: potentials and failuresEndovascular thrombectomy following acute ischemic stroke: a single-center case series and critical review of the literature.Ancillary approaches to plasminogen activators.Advances in ischemic stroke treatment: neuroprotective and combination therapies.Efficacy and safety of desmoteplase in acute ischemic stroke patients: A systematic review and meta-analysis.Longistatin, a plasminogen activator, is key to the availability of blood-meals for ixodid ticksImaging-based treatment selection for intravenous and intra-arterial stroke therapies: a comprehensive review.Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence.Intravenous thrombolytics for ischemic stroke.Desmoteplase: discovery, insights and opportunities for ischaemic stroke.Potential for discovery of neuroprotective factors in serum and tissue from hibernating speciesExtracellular proteolytic pathophysiology in the neurovascular unit after stroke.Endothelial cells and astrocytes: a concerto en duo in ischemic pathophysiology.Advances in revascularization for acute ischemic stroke treatment.Advances in thrombolytics and mechanical devices for treatment of acute ischemic stroke.Endovascular management of acute ischemic stroke: advances in patient and treatment selection.Desmoteplase in the treatment of acute ischemic stroke.Combined intravenous and intra-arterial approach in acute stroke treatment.Neuroprotection and stroke: time for a compromise.Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possiblyIntravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillationExtending the time window for stroke treatment: advanced brain imaging +/- bat saliva.Desmoteplase.Pharmacotherapy of cerebral ischemia.Therapeutic targets for neuroprotection in acute ischemic stroke: lost in translation?Proteases as therapeutics.How to make better use of thrombolytic therapy in acute ischemic stroke.Improving reperfusion therapy for acute ischaemic stroke.Advances in revascularization for acute ischemic stroke treatment: an update.Plasminogen activation and thrombolysis for ischemic stroke.Serine-proteases as plasminogen activators in terms of fibrinolysis.The use of desmoteplase (bat saliva) in the treatment of ischaemia.Desmoteplase as a potential treatment for cerebral ischaemia.Clinical trials in acute ischemic stroke.Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.Is there potential for antioxidants to enhance thrombolysis therapy in patients with ischemic stroke?Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling.
P2860
Q26777261-BAB797E4-D3EE-47E4-82FD-CC403E2075D3Q26782904-15AAD962-6BFC-42DD-A8B9-D3E7EB2FD0B0Q26825758-B095657B-6FE8-4989-B7D1-DFF0E67180B4Q30436396-44A8516D-54B7-4713-BADD-9ECB0E942213Q31095961-B36B226B-B603-45EF-99C3-9B565F45ED0AQ33278117-13F05E38-A8C7-4109-8F01-3D2A72FCB9C0Q33644102-FDD7E144-0AB3-4F7D-9DC2-8AABE95AF1C9Q33851506-EFDC268F-F5F2-42B3-B63F-698BA82DC461Q33978760-C239A4D9-CAA7-4BE4-9BEA-48EA70BAE973Q34006140-02C1EC7B-D932-4F49-8F8A-E4A97AFB76E9Q35648096-1F0C4BC6-D751-402F-AD02-88B9DADCAEA9Q35657910-55EEBE83-DE0F-45E6-998F-AB7772654101Q35679741-AB410ACD-CFE9-4453-AF51-BF3C5708DD70Q36052713-88601FE3-1611-455E-B317-05EECBC59732Q36072867-933B1868-5146-401C-8C87-DBAB39AB51DAQ36106802-D5187C36-682C-4F19-A65D-563999F340C0Q36273735-3CECCF12-A3C4-4C4A-AEF2-8843C7F9C85CQ36730655-3BF2F91D-9A02-4EB0-BFBE-4ED4AF3FC550Q36787325-4D414D09-D0E8-4E3C-A5F5-C9AA5B439C17Q36909262-4DEE3F19-4F34-408E-A863-93961459F84AQ36922560-1F706FCB-0209-4DD1-A7D3-CEB067DD745FQ37024492-9BE4FD7E-8FD6-4AF9-B53A-3270612DF35BQ37314662-2BCC6A70-C221-49E4-8D37-DEB7667CA667Q37316471-D4C4C94B-19E7-47B7-B3F2-B9316FB0030AQ37453625-BDA0DF65-3CB1-445C-944C-B9C81540D463Q37489895-226D0858-5AAE-4368-A528-2F2CA28FCE9BQ37514167-0401FB3A-8BFE-4932-A1AE-E21B3DD5B75EQ37772176-5D333F7B-B67E-4712-A1EA-CE5E2AE2EAF7Q37853216-1B3BCAE0-1E1D-4FD9-8DE4-C68E4AECAD1DQ37889116-F47ABF7F-4FD0-4FCE-95DF-EA36A3BB4AF6Q37903959-5197D14F-2BE0-4867-BFC6-46A87FC52389Q37907291-1D7FFB2F-7078-4AD0-A19D-BFFF5A264507Q37998537-B9D60900-E177-4425-B501-96B45E899F21Q38024834-83F3726D-D413-4146-B67A-A74D362DF9E5Q38080143-4CAE0B7B-BF08-4066-A065-5D51C4629E21Q38207146-EED16992-23CD-4B38-86FF-E69E6AB2FFDEQ38243696-671E747B-99F7-44C6-A0CE-6F882A719352Q38917550-1EEA62CE-E70D-41D2-B728-3BFD2CA9FFACQ40274650-344D8FE5-1DE5-4160-94DA-5513958EC14EQ40511087-4DBF2678-E104-490E-BBDF-86F5F85FD01E
P2860
Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Vampire bat salivary plasminog ...... not promote neurodegeneration
@ast
Vampire bat salivary plasminog ...... not promote neurodegeneration
@en
Vampire bat salivary plasminog ...... not promote neurodegeneration
@nl
type
label
Vampire bat salivary plasminog ...... not promote neurodegeneration
@ast
Vampire bat salivary plasminog ...... not promote neurodegeneration
@en
Vampire bat salivary plasminog ...... not promote neurodegeneration
@nl
prefLabel
Vampire bat salivary plasminog ...... not promote neurodegeneration
@ast
Vampire bat salivary plasminog ...... not promote neurodegeneration
@en
Vampire bat salivary plasminog ...... not promote neurodegeneration
@nl
P2093
P1433
P1476
Vampire bat salivary plasminog ...... not promote neurodegeneration
@en
P2093
Christopher Bladin
Gabriel T Liberatore
Robert L Medcalf
Wolf-Dieter Schleuning
P304
P356
10.1161/01.STR.0000049764.49162.76
P407
P577
2003-02-01T00:00:00Z